Business
07 Jun, 2026
Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply
Business To Business, New Delhi, 7th June, 2026: Shokhrukh Gulamov has said that Uzbekistan is considering stronger incentives to attract investment from Indian pharmaceutical companies.
The proposed measures include enhanced subsidies, tax incentives, and support for technology transfer to encourage pharmaceutical manufacturing within Uzbekistan.
Gulamov said the country aims to position itself as a regional hub for pharmaceutical production and supply.
Proposed Reforms
According to the deputy minister, Uzbekistan could make investment more attractive by:
- Simplifying regulatory and licensing procedures.
- Reducing bureaucratic hurdles for investors.
- Providing more predictable approval timelines.
- Offering tax benefits and subsidies for technology transfer.
- Encouraging participation in industrial clusters.
- Supporting export-oriented pharmaceutical production.
Why India Matters
India is one of the world's largest producers of generic medicines and pharmaceutical products. Attracting Indian firms could help Uzbekistan:
- Expand domestic drug manufacturing capacity.
- Reduce dependence on imports.
- Gain access to advanced pharmaceutical technologies and expertise.
- Develop export capabilities for regional markets in Central Asia and beyond.
Strategic Significance
For Uzbekistan, the initiative is part of a broader effort to diversify its industrial base and attract foreign direct investment. For Indian pharmaceutical companies, the country could serve as a gateway to Central Asian and Eurasian markets, supported by potential government incentives and a more streamlined regulatory environment.
Key takeaway: Uzbekistan is signaling its willingness to offer stronger incentives—including tax benefits, subsidies, and easier regulations—to attract Indian pharmaceutical manufacturers and build a larger domestic pharmaceutical industry with regional export ambitions.